Alpine Immune Sciences (ALPN)
(Delayed Data from NSDQ)
$64.56 USD
-0.06 (-0.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $64.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.56 USD
-0.06 (-0.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $64.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
by Zacks Equity Research
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
by Zacks Equity Research
Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 146.88% and 346.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
StoneCo (STNE) to Post Q4 Earnings: What's in the Offing?
by Zacks Equity Research
StoneCo's (STNE) fourth-quarter 2023 performance will likely reflect strength in its financial services and software business.
Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?
by Zacks Equity Research
Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Revenue Decline Impact Jabil's (JBL) Q2 Earnings?
by Zacks Equity Research
Jabil (JBL) is expected to report a top-line contraction year over year in the second quarter of fiscal 2024, owing to soft demand trends in several business segments.
Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Adobe's (ADBE) first-quarter fiscal 2024 results are expected to reflect gains from the solid momentum across the Digital Media and Digital Experience segments.
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SentinelOne (S) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
SentinelOne's (S) fourth-quarter fiscal 2024 performance is expected to have benefited from its robust growth in the Singularity platform.
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 13.04% and 11.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical
by Zacks Equity Research
Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Wall Street Analysts See a 56.25% Upside in Alpine Immune Sciences, Inc. (ALPN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 56.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Wall Street Analysts Think Alpine Immune Sciences, Inc. (ALPN) Could Surge 79.37%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 79.4% in Alpine Immune Sciences, Inc. (ALPN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Alcon (ALC) This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for October 23rd
by Zacks Equity Research
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.